|
|
Volumn 18, Issue SUPPL. 1, 2011, Pages 135-136
|
|
Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BORTEZOMIB;
BRAIN NATRIURETIC PEPTIDE;
DEXAMETHASONE;
IMMUNOGLOBULIN LIGHT CHAIN;
MELPHALAN;
THALIDOMIDE;
TROPONIN I;
ADJUVANT THERAPY;
ADULT;
AMYLOIDOSIS;
ARTICLE;
AUTOLOGOUS STEM CELL TRANSPLANTATION;
CLINICAL ARTICLE;
DISEASE COURSE;
DRUG EFFICACY;
DRUG MEGADOSE;
FEMALE;
FOLLOW UP;
GASTROINTESTINAL TOXICITY;
HUMAN;
INFECTION;
LIGHT CHAIN AMYLOIDOSIS;
MALE;
MULTIPLE CYCLE TREATMENT;
OVERALL SURVIVAL;
PERIPHERAL NEUROPATHY;
PRIORITY JOURNAL;
REMISSION;
RISK ASSESSMENT;
THROMBOCYTOPENIA;
TREATMENT DURATION;
TREATMENT RESPONSE;
BORONIC ACIDS;
COMBINED MODALITY THERAPY;
DEXAMETHASONE;
HUMANS;
MELPHALAN;
PYRAZINES;
STEM CELL TRANSPLANTATION;
|
|
EID: 79959927379
PISSN: 13506129
EISSN: 17442818
Source Type: Journal
DOI: 10.3109/13506129.2011.574354 Document Type: Article |
|
Times cited : (18)
|
|
References (5)
|
